Overview

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Status:
Completed

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.

Phase:

Phase 3

Details

Lead Sponsor:

Drugs for Neglected Diseases

Collaborators:

International Centre for Diarrhoeal Disease Research, Bangladesh
Shaheed Surhawardy Medical College and Hospital

Treatments:

Amphotericin B
Liposomal amphotericin B
Miltefosine
Paromomycin